Hormone therapy (HRT/MHT) has had a complicated history. Here, in short, is what the current evidence shows: for women under 60 or within 10 years of menopause, the benefits of treatment generally outweigh the risks, and reanalyses of the Women's Health Initiative data have corrected much of the fear that followed 2002. The decision remains a personal one, to be made with a doctor on the basis of your complete history.
Two things make this subject harder than it needs to be. The first is that the evidence itself is genuinely complicated. The second is that most women met it as a headline rather than as an explanation. This guide works through the biology first, then the evidence, and finally the practical question: what would this mean for you, and what should you ask.
What does hormone therapy actually change in the body?
Estrogen is not one substance with one job. It works by binding to receptors, which are docking sites on cells in many different tissues. When estrogen fits the receptor, it changes what that cell does. Receptors are not spread evenly through the body, and that unevenness is part of why two women of the same age can have completely different symptoms.
The tissues that matter most for menopausal symptoms are the hypothalamus, which runs the body's temperature control, and bone, where estrogen helps hold the balance between building and breaking down. Estrogen also acts on the lining of the vagina and urinary tract, on skin and connective tissue, on blood vessels, and on parts of the brain involved in mood, sleep and memory.
In perimenopause, estrogen does not fall in a straight line. It swings. The brain's thermostat reacts to the swings as much as to the low level, which is why symptoms often begin while periods are still regular.
Hormone therapy gives back enough estrogen to occupy those receptors again. It does not restore a menstrual cycle or fertility, and it is not the same as the estrogen a younger body produces on its own. It is a treatment that fills a gap, not a restoration of an earlier state.
Progesterone is the second half of the story. In a cycling body, it prepares and then stabilizes the lining of the uterus each month. When estrogen is given on its own to a woman who still has a uterus, that lining is stimulated without the brake that normally follows. Over time, that unopposed stimulation is what raises the risk of cancer of the uterine lining. A progestogen restores the brake. This is why the progestogen part is not optional for a woman with a uterus. It is also why a woman who has had a hysterectomy can take estrogen alone.
One consequence is worth stating plainly. The benefit and the risk come from the same mechanism. Estrogen acting on a tissue is what relieves a symptom, and it is also what changes a risk. There is no version of this treatment that keeps only the first half.
The WHI reanalysis — what actually changed:
The 2002 Women's Health Initiative findings led millions of women to stop HRT, and the echo of that moment is still felt today. But 18-year cumulative follow-up (Manson et al., JAMA 2017; 2018) painted a more nuanced picture:
- All-cause, cardiovascular, and cancer mortality: NO statistically significant difference between HT and placebo (HR 0.99, 95% CI 0.94-1.03)
- Estrogen-alone (women with prior hysterectomy): NO increased breast cancer risk — in fact, a trend toward reduced incidence
- Timing confirmed: women who started HT within 10 years of menopause had more favorable outcomes
- In February 2026, the FDA removed 'black box' warnings from most HT products
Why did it take so long? Because the women in the original trial were, on average, older and further from menopause than those who start treatment today, and that difference explains much of the negative reporting from the early years.
Absolute vs. relative risk — an essential distinction:
Much of the fear around HRT comes from quoting relative risk, which describes a proportional increase, not the real size of the problem. Absolute risk shows how many additional cases actually occur in a given number of women — and it is far easier to interpret in real life. This distinction explains why studies of the same treatment can look contradictory at first glance.
The absolute risk picture (BMJ Harper et al., 2024):
When risk is expressed in absolute numbers, the picture becomes clear:
- The absolute risk of breast cancer with estrogen-plus-progestogen HRT is fewer than 1 additional case per 1,000 women per year of use
- For estrogen-alone therapy, no increased risk was found across all follow-up periods
- This places HRT's risk profile in the same range as many over-the-counter medications
A risk of fewer than one additional case per thousand women per year is hard to detect at the individual level. This is exactly the context that was missing from the public debate back then, when risks were presented almost exclusively in relative terms.
Why the same evidence can support opposite headlines:
There are two main ways to study a treatment, and they answer different questions.
A randomized controlled trial assigns women to the treatment or to a placebo by chance. Chance is the point. It is the only reliable way to balance the two groups on everything the researchers did not think to measure. That is why a randomized trial can support a statement about cause.
An observational study follows women who make their own choices. That design answers a real question, but it carries a built-in problem. Women who seek hormone therapy are often different in ways that matter. They may see a doctor more often, or be healthier, wealthier, or more health-conscious to begin with. Those differences can produce a result that looks like the effect of the drug but is not. Researchers call this confounding. A careful observational study adjusts for everything it managed to record. It can never adjust for what nobody recorded.
Both designs are useful. Neither is a lie. But they cannot carry the same weight, and a headline rarely says which one it came from.
The Women's Health Initiative shows why even a single dataset can look contradictory. The trial reported an average effect across all the women in it. That average was real. But an average hides who was helped and who was not. When the same results were examined later by age, and by how far each woman was from menopause, the picture split apart. Younger women close to menopause and older women far past it were not the same story. Both readings came from one dataset. Neither was invented.
Three other things change the answer without changing the truth. What the study measured, whether deaths, heart attacks or a symptom score, can differ between two reports of the same trial. How long the women were followed changes what can be seen at all. And whether a result is expressed as a relative or an absolute risk changes how alarming it sounds.
So when you meet a risk figure, ask three questions. Compared with what? In how many people? Over how long? A number without those three answers cannot tell you what to do.
Current clinical recommendations (NICE updated April 2026, The Menopause Society, Endocrine Society):
Guidelines have been realigned with these data. Here are the essential points they make today:
- HRT is first-line for moderate-to-severe vasomotor symptoms — Cochrane (Grant et al., 2019) confirms a ~75% reduction in hot flash frequency vs placebo
- For women under 60 or within 10 years of menopause, benefits outweigh risks — this is the 'window of opportunity' supported by the WHI reanalysis
- For premature ovarian insufficiency (under 40), HRT is strongly recommended; benefits significantly outweigh risks in this population
- Low-dose oral estradiol (0.5 mg/day): a randomized trial (JAMA, n=225 perimenopausal/postmenopausal women) found it reduced vasomotor symptom frequency by 52.9% vs 28.6% placebo at 8 weeks
- Transdermal estrogen (patch, gel) carries a lower risk of blood clots than oral estrogen
- Compounded bioidentical hormones are NOT recommended — they lack FDA regulation
The 'window of opportunity' describes the period in life when the body responds best to estrogen and risks are lowest. The route of administration also matters: choosing between oral and transdermal forms is something to do with your doctor, based on your personal risk factors.
Key NICE 2026 updates:
Alongside HRT's therapeutic role, the guidelines clarified what should not be done routinely:
- Do NOT use FSH testing to diagnose menopause in women aged 45+ with typical symptoms — the diagnosis is clinical
- HRT should not be routinely offered solely for cardiovascular prevention
- CBT is recommended for low mood, anxiety, and hot flash bother
These clarifications do not diminish the value of HRT where it is indicated; they simply show that each indication has a specific purpose.
Why the route of delivery changes the risk:
A tablet is swallowed. It is absorbed through the gut and then carried straight to the liver before it reaches the rest of the body. That first pass matters more than it sounds, because the liver is where the body makes many of the proteins involved in clotting. Estrogen arriving there in a concentrated dose can push those proteins in a direction that favors clots.
The same estrogen, absorbed through the skin, enters the bloodstream gradually and largely avoids that first pass. The hormone is the same family either way. What changes is what the liver is exposed to. That is why the route is a clinical decision rather than a matter of preference.
| Route | How it reaches the body | What it is used for | Why it may be chosen |
|---|---|---|---|
| Oral (tablet) | Swallowed and absorbed from the gut, reaching the liver before the rest of the body | Systemic symptoms such as hot flashes and night sweats | Simple and well studied |
| Transdermal (patch, gel) | Absorbed through the skin into the bloodstream | Systemic symptoms such as hot flashes and night sweats | Bypasses the first pass through the liver, which is why the clot picture differs |
The choice between them is rarely about how well they work. It is about your own risk factors, and about what you can live with day to day.
What is settled, and what is still open:
Settled: the points the guidance now states plainly.
- Hormone therapy relieves hot flashes and night sweats more effectively than placebo
- It protects bone, and that effect is measurable
- For women under 60 or within 10 years of menopause, the balance of benefits and risks is favourable
- A woman who still has a uterus needs a progestogen alongside estrogen
- The route of delivery changes the clot risk
- Compounded bioidentical products are not recommended, because they are not regulated as licensed medicines are
Still open: the questions a clinician and a patient still have to weigh together.
- How hormone therapy fits into heart protection over the long term. The guidance is clear that it should not be prescribed for that purpose alone. What it does to cardiovascular risk while it is being taken for symptoms is a separate question, and one that is still discussed
- Whether long-term use affects memory and thinking. Studies point in more than one direction, and the answer may depend on when treatment begins
- Which progestogen suits which woman, particularly for sleep and mood. The options differ, and the evidence does not choose for you
- How to weigh the balance when symptoms are moderate rather than severe. The guidance is written for moderate-to-severe symptoms. In between, it is a judgement
- How a woman's own history, including family risk, blood pressure, migraine and previous clots, should shift the calculation. That part is individual by definition
- What happens to risk over decades of use, and what the picture looks like after stopping
The large questions have answers. The small ones do not, and the small ones are where your appointment happens.
How to talk to your doctor:
Before any decision, a doctor will want to know your personal and family history, your age, when menopause began, and any existing conditions. Prepare a list of the symptoms that bother you most, and ask directly which options fit your situation, what risks they carry, and when you might expect improvement. Not all doctors are equally up to date on the latest evidence; if you feel the conversation stays superficial, ask for a specialist.
What to track before an appointment:
- Your symptoms, listed one by one. For each, note how often it happens and how much it interferes with sleep, work or relationships
- Your bleeding pattern: whether you still have periods, how they have changed, and any bleeding between them
- Any migraines, and how they present
- Your blood pressure readings, if you take them at home, and any recent test results
- Every medicine, supplement and herbal product you take, including anything bought without a prescription
- Your family history: breast and ovarian cancer, clots, heart disease, stroke, and early menopause in close relatives
- When your periods changed, and when they stopped, as precisely as you can remember
- What you have already tried, and what happened
Questions worth asking:
- Which symptom are we treating first, and what improvement should I expect?
- Which form suits my history, and why that one?
- What would make you change the plan?
- What should send me back to you sooner?
- If I have a uterus, is my progestogen covered?
- Is anything I already take a problem with this?
- How long do we give this before we decide whether it is working?
- What is the plan if I want to stop?
If a concern gets dismissed:
- Say what you need, not only how you feel. "I need to know whether this is safe for me" is a request that is hard to talk around
- Ask for the reasoning to be written down, so you can read it again later
- Ask for a second opinion, or for a referral to someone who specializes in menopause. You do not need permission to ask
- Take notes, or take someone with you. Appointments are short, and it is easy to leave without asking the thing you came for
- If you are told your symptoms are normal for your age, ask what can be done about them anyway. Normal and treatable are not opposites
- If you are told hormone therapy is dangerous without any discussion of your own history, get another view. That is not a reason to give up
Misunderstandings that keep women from asking:
Some beliefs are so widespread that they end the conversation before it starts. Each holds a grain of something real, which is why they last.
- "The 2002 headlines settled it." They did not. The same body of research was re-examined over years of follow-up. The picture that emerged was more favourable than the first reports suggested, particularly for women near menopause
- "A percentage told me everything I need to know." A relative risk is a proportion. Without the base rate underneath it, it cannot tell you how likely anything is for you. That missing number is where much of the fear came from
- "Bioidentical means safer." The word describes a chemical structure, not a manufacturing standard. A licensed body-identical product and one compounded in a pharmacy are not the same thing. It is the compounded kind that guidance advises against
- "It is just my age." Hot flashes are common at this stage of life. Common is not the same as untreatable, and the guidance treats moderate-to-severe vasomotor symptoms as something to treat rather than to endure
- "If it mattered, my doctor would have raised it." Not every clinician is equally current on this subject. That is exactly why it is worth arriving with your own questions
- "Asking makes me difficult." Asking is what the appointment is for
None of this is an argument for taking hormone therapy. These are reasons not to rule it out before the conversation has happened. The decision belongs to you, and it is a better decision when it is made with information rather than with a headline.
In short:
Hormone therapy replaces hormones the body is no longer producing in the same way, and it acts on many tissues at once. That is why the benefit and the risk arrive together. The evidence has been hard to read. Observational and randomized studies answer different questions, and a relative risk without a base rate tells you very little. What is settled: therapy relieves vasomotor symptoms and protects bone. The balance is favourable in the window, and the route changes the clot picture. What is open is how all of it weighs for one woman with one history. That is what the appointment is for: bring your symptoms, your history and your questions.